GENETIC BIOMARKERS OF GLIAL BRAIN TUMORS: IDH1 AND IDH2 MUTATIONS

Introduction. Mutations in the isocytrate dehydrogenase 1 and 2 genes (IDH1 and IDH2) are considered driver genetic events in gliomas. Their frequency reaches 7080 % in low-grade gliomas and in secondary glioblastomas, and their oncogenic effect is realized by accumulation of the metabolite 2-hydroxyglutarate, which disrupts DNA and protein methylation processes.
The aim of the study was to analyze the associations between the presence of IDH1/2 mutations and clinical and morphological parameters of glial tumors.
Material and Methods. The study included 147 patients with glial brain tumors. Associations between IDH1/2 status and tumor histological type, age of disease onset, tumor localization, and clinical manifestations were investigated.
Results. Gliomas containing IDH1/2 mutations were characterized by a younger age at diagnosis (mean: 39.5 years) compared to IDH-negative cases (47.2 years) (p<0.01). IDH1/2-mutated tumors were more often localized in the frontal (53.4 %) and parietal lobes (61.3 %) than in the other areas of the brain (p<0.05). It was demonstrated that the incidence of epilepsy was significantly higher among patients with IDH1/2 genetic defects (69.2 % vs. 48.2 %, p<0.05). Patients with IDH1/2 mutations had more favorable course of the disease. Among individuals with a combination of these factors (localization of the tumor in the frontal or parietal lobe, presence of epilepsy, age younger than 39 years), the frequency of IDH1/2 mutations reached 21/27 (77.8 %), which was significantly higher than that in all other patients (44/119 (37.0 %), OR = 5.97, 95 % CI: 2.2415.91, p<0.001).
Conclusion. The presence of IDH1/2 genetic defects is associated with localization of glial tumors in the frontal and parietal lobes of the brain, earlier age at disease onset and the presence of epileptic syndrome.

epilepsy, seizure, IDH1 and IDH2 gene mutations, gliomas, glioblastoma, anaplastic astrocytoma, diffuse astrocytoma, brain tumors

1. Ostrom Q.T., Gittleman H., Liao P., Vecchione-Koval T., Wolinsky Y., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 20102014. Neuro Oncol. 2017 Nov 6; 19(suppl_5): v1v88. doi: 10.1093/neuonc/nox158.

2. Carson K.A., Grossman S.A., Fisher J.D., Shaw E.G. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007 Jun 20; 25(18): 2601–6. doi: 10.1200/JCO.2006.08.1661.

3. Curran W.J.Jr., Scott C.B., Horton J., Nelson J.S., Weinstein A.S., Fischbach A.J., Chang C.H., Rotman M., Asbell S.O., Krisch R.E. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993 May 5; 85(9): 704–10. doi: 10.1093/jnci/85.9.704.

4. Iwabuchi S., Bishara S., Herbison P., Erasmus A., Samejima H. Prognostic factors for supratentorial low grade astrocytomas in adults. Neurol Med Chir (Tokyo). 1999 Apr; 39(4): 273–9. doi: 10.2176/nmc.39.273.

5. Lamborn K.R., Chang S.M., Prados M.D. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol. 2004 Jul; 6(3): 227–35. doi: 10.1215/S1152851703000620.

6. Martynov B.V., Parfenov V.E., Trufanov G.E., Fokin V.A., Alexeyeva N.P., Tsibirov A.A., Holyavin A.I., Gracheva P.V., Smirnov I.B., Svistov D.V. Prognostic factors of patients with gliomas: symptomatic-syndrome analysis. Bulletin of the Russian Military Medical Academy. 2010; 1(29): 7–14. (in Russian).

7. Lynam L.M., Lyons M.K., Drazkowski J.F., Sirven J.I., Noe K.H., Zimmerman R.S., Wilkens J.A. Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg. 2007; 109(7): 634–8. doi: 10.1016/j.clineuro.2007.05.017.

8. Ozbek N., Cakir S., Gursel B., Meydan D. Prognostic significance of seizure in patients with glioblastoma multiforme. Neurol India. 2004 Mar; 52(1): 76–8.

9. Matsko D.E., Matsko M.V., Imyanitov E.N. Neurooncology. Practical Oncology. 2017; 18(1): 103–14. (in Russian).

10. Stockhammer F., Misch M., Helms H.J., Lengler U., Prall F., von Deimling A., Hartmann C. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure. 2012; 21(3): 194–7. doi: 10.1016/j.seizure.2011.12.007.

11. Duan W.C., Wang L., Li K. IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas. Medicine (Baltimore). 2018; 97(50): e13675. doi: 10.1097/MD.0000000000013675.

12. Chen H., Judkins J., Thomas C., Wu M., Khoury L., Benjamin C.G., Pacione D., Golfinos J.G., Kumthekar P., Ghamsari F., Chen L., Lein P., Chetkovich D.M., Snuderl M., Horbinski C. Mutant IDH1 and seizures in patients with glioma. Neurology. 2017; 88(19): 1805–13. doi: 10.1212/WNL.0000000000003911.

13. Phan K., Ng W., Lu V.M., McDonald K.L., Fairhall J., Reddy R., Wilson P. Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis. World Neurosurg. 2018 Mar; 111: e539-e545. doi: 10.1016/j.wneu.2017.12.112.

14. Yang Y., Mao Q., Wang X., Liu Y., Mao Y., Zhou Q., Luo J. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy. J Clin Neurosci. 2016 Sep; 31: 56–62. doi: 10.1016/j.jocn.2015.11.030.

15. Prokudin M.Yu., Odinak М.M., Litvinenko I.V., Martynov B.V., Zheleznyak I.S., Lytkin М.V., Okolzin A.V., Vorontsova D.А. Magnetic Resonance Spectroscopy in Cerebral Gliomas: Biologic Markers. Neurology. Psychiatry. 2018; 1(145): 10–15. (in Russian).

16. Chen R., Ravindra V.M., Cohen A.L., Jensen R.L., Salzman K.L., Prescot A.P., Colman H. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus. 2015 Mar; 38(3): E2. doi: 10.3171/2015.1.FOCUS14745.

17. Tabakov D.V., Katargin A.N., Stroganova A.M., Senderovich A.I., Naskhletashvili D.R., Kiseljova N.P. Isocitrate dehydrogenase 1 and 2 genes mutations and MGMT methylation in gliomas. Advances in Molecular Oncology. 2017; 4: 53–59. (in Russian). doi: 10.17650/2313-805X-2017-4-1-53-59.

18. Lobanova N.V., Shishkina L.V., Ryzhova M.V., Kobyakov G.L., Sycheva R.V., Burov S.A., Lukyanov A.V., Omarova Zh.R. Clinical, immunohistochemical, and molecular genetic prognostic factors in adult patients with glioblastoma. Archive of Pathology. 2016; 78(4): 10–19. (in Russian). doi: 10.17116/patol201678410-19.

19. Schittenhelm J., Mittelbronn M., Meyermann R., Melms A., Tatagiba M., Capper D. Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma. Acta Neuropathol. 2011 Nov; 122(5): 651–2. doi: 10.1007/s00401-011-0885-0.